In case you didn’t see the big news this week, Pfizer has announced that the preliminary results from the “Phase 3, late-stage study” of their COVID-19 vaccine show that it is “more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.”
. . . Except for just a couple of teensy-weensy little problems. Like the fact that this announcement is just that: an announcement. There is no data to scrutinize here, nothing presented for public review (let alone peer review). This is a press release, literal corporate PR and nothing more.